Literature DB >> 8442999

Bone mineral density measured by dual energy x-ray absorptiometry in patients with non-insulin-dependent diabetes mellitus.

M Wakasugi1, R Wakao, M Tawata, N Gan, K Koizumi, T Onaya.   

Abstract

Because of the previous controversial findings in diabetic patients with older methodologies, we assessed bone mineral density (BMD) in 78 patients (38 males and 40 females) with non-insulin-dependent diabetes mellitus using dual energy x-ray absorptiometry (DEXA). BMD was measured in lumbar vertebrae (L2-4). The BMD of each patient was calculated as the percentage of the mean value (%BMD) obtained from a healthy control group matched for sex and age. The %BMD of the patients with diabetes was about 100% for females and 96% for males, as compared with BMD of normal controls. The %BMD of the patients with diabetes was significantly correlated with body mass index and urinary C peptide level, and inversely correlated with age and duration of diabetes within 20 years. No relationships were found between %BMD and serum calcium, phosphorus, or glycosylated hemoglobin A1C levels. These observations suggest that metabolic abnormalities associated with diabetes mellitus alter the BMD, and that such factors as duration of the disease and deficit in insulin secretion are risk factors for decreased BMD.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8442999     DOI: 10.1016/8756-3282(93)90252-6

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  25 in total

Review 1.  Hormone replacement therapy in postmenopausal women with diabetes mellitus: a risk-benefit assessment.

Authors:  B Andersson
Journal:  Drugs Aging       Date:  2000-11       Impact factor: 3.923

2.  The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes.

Authors:  Emily Jane Gallagher; Hui Sun; Caroline Kornhauser; Aviva Tobin-Hess; Sol Epstein; Shoshana Yakar; Derek LeRoith
Journal:  Diabetes Metab Res Rev       Date:  2014-03       Impact factor: 4.876

3.  Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats.

Authors:  T Shibata; S Takeuchi; S Yokota; K Kakimoto; F Yonemori; K Wakitani
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

4.  Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk.

Authors:  P Vestergaard; L Rejnmark; L Mosekilde
Journal:  Diabetologia       Date:  2005-05-21       Impact factor: 10.122

5.  Bone quantitative ultrasound measurements in relation to the metabolic syndrome and type 2 diabetes mellitus in a cohort of elderly subjects at high risk of cardiovascular disease from the PREDIMED study.

Authors:  M Bulló; M Garcia-Aloy; J Basora; M I Covas; J Salas-Salvado
Journal:  J Nutr Health Aging       Date:  2011-12       Impact factor: 4.075

6.  Thiazolidinediones and bone.

Authors:  Alberto Falchetti; Laura Masi; Maria Luisa Brandia
Journal:  Clin Cases Miner Bone Metab       Date:  2007-05

Review 7.  Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients?

Authors:  Guojing Luo; Hong Liu; Hongyun Lu
Journal:  Br J Clin Pharmacol       Date:  2016-01       Impact factor: 4.335

8.  Increasing serum osteocalcin after glycemic control in diabetic men.

Authors:  S Sayinalp; O Gedik; Z Koray
Journal:  Calcif Tissue Int       Date:  1995-12       Impact factor: 4.333

9.  Bone mineral density in the femur and lumbar vertebrae decreases after twelve weeks of diabetes in spontaneously diabetic-prone BB/Worcester rats.

Authors:  C E Waud; S C Marks; R Lew; D T Baran
Journal:  Calcif Tissue Int       Date:  1994-03       Impact factor: 4.333

Review 10.  Correlation between osteoporosis and cardiovascular disease.

Authors:  Delia Sprini; Giovam Battista Rini; Laura Di Stefano; Luisella Cianferotti; Nicola Napoli
Journal:  Clin Cases Miner Bone Metab       Date:  2014-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.